Observational studyJournal of viral hepatitis2019

Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.

Peter Ferenci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.